Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Dose Tolerability and Efficacy Study of RX-0201 Plus Gemcitabine in Metastatic Pancreatic Cancer

NCT01028495 is registered in ClinicalTrials.gov with Rexahn Pharmaceuticals, Inc. as lead sponsor.

NCT NCT01028495
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01028495 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Dose Tolerability and Efficacy Study of RX-0201 Plus Gemcitabine in Metastatic Pancreatic Cancer
Lead sponsor
Rexahn Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2009
Completion date
August 31, 2012
Enrollment
31 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic pancreatic cancer